|
1
|
Kostin NN, Bobik TV, Skryabin GA, Simonova MA, Knorre VD, Abrikosova VA, Mokrushina YA, Smirnov IV, Aleshenko NL, Kruglova NA, Mazurov DV, Nikitin AE, Gabibov AG. An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity. Acta Naturae 2022; 14:109-119. [PMID: 36348715 PMCID: PMC9611858 DOI: 10.32607/actanaturae.11776] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 08/22/2022] [Indexed: 11/22/2022] Open
Abstract
Monitoring of the level of the virus-neutralizing activity of serum immunoglobulins ensures that one can reliably assess the effectiveness of any protection against the SARS-CoV-2 infection. For SARS-CoV-2, the RBD-ACE2 neutralizing activity of sera is almost equivalent to the virus-neutralizing activity of their antibodies and can be used to assess the level of SARS-CoV-2 neutralizing antibodies. We are proposing an ELISA platform for performing a quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies, as an alternative to the monitoring of the virus-neutralizing activity using pseudovirus or "live" virus assays. The advantage of the developed platform is that it can be adapted to newly emerging virus variants in a very short time (1-2 weeks) and, thereby, provide quantitative data on the activity of SARS-CoV-2 RBD-neutralizing antibodies. The developed platform can be used to (1) study herd immunity to SARS-CoV-2, (2) monitor the effectiveness of the vaccination drive (revaccination) in a population, and (3) select potential donors of immune plasma. The protective properties of the humoral immune response in hospitalized patients and outpatients, as well as after prophylaxis with the two most popular SARS-CoV-2 vaccines in Russia, were studied in detail using this platform. The highest RBD-neutralizing activity was observed in the group of hospitalized patients. The protective effect in the group of individuals vaccinated with Gam-COVID-Vac vaccine was 25% higher than that in outpatients and almost four times higher than that in individuals vaccinated with the CoviVac vaccine.
Collapse
Affiliation(s)
- N. N. Kostin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| | - T. V. Bobik
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| | - G. A. Skryabin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| | - M. A. Simonova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| | - V. D. Knorre
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| | - V. A. Abrikosova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| | - Y. A. Mokrushina
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| | - I. V. Smirnov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| | - N. L. Aleshenko
- Central Clinical Hospital of the Russian Academy of Sciences, Moscow, 117593 Russia
| | - N. A. Kruglova
- Institute of Gene Biology Russian Academy of Sciences, Moscow, 119334 Russia
| | - D. V. Mazurov
- Institute of Gene Biology Russian Academy of Sciences, Moscow, 119334 Russia
| | - A. E. Nikitin
- Central Clinical Hospital of the Russian Academy of Sciences, Moscow, 117593 Russia
| | - A. G. Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, 117997 Russia
| |
Collapse
|
|
2
|
Krut VG, Astrakhantseva IV, Chuvpilo SA, Efimov GA, Ambaryan SG, Drutskaya MS, Nedospasov SA. Antibodies to the N-Terminal Domain of Angiotensin-Converting Enzyme (ACE2) That Block Its Interaction with SARS-CoV-2 S Protein. DOKL BIOCHEM BIOPHYS 2021; 502:1-4. [PMID: 34874527 PMCID: PMC8649309 DOI: 10.1134/s160767292201001x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Revised: 10/15/2021] [Accepted: 10/15/2021] [Indexed: 11/23/2022]
Abstract
SARS-CoV-2 is a new coronavirus that is the cause of COVID-19 pandemic. To enter the cell, the virus interacts via its surface S protein with angiotensin-converting enzyme 2 (ACE2), the main entry receptor on the cell membrane. Most of protective antibodies, including those induced by vaccinations, target the S protein, preventing its interaction with the ACE2 receptor. We have evaluated an alternative strategy for blocking the S-ACE2 interaction using new antipeptide antibodies to the N-terminus of the ACE2 molecule. These antibodies allow detection of human ACE2 in vitro and ex vivo.
Collapse
Affiliation(s)
- V G Krut
- Sirius University of Science and Technology, Federal Territory Sirius/Sochi, Russia
| | - I V Astrakhantseva
- Sirius University of Science and Technology, Federal Territory Sirius/Sochi, Russia
| | - S A Chuvpilo
- Sirius University of Science and Technology, Federal Territory Sirius/Sochi, Russia
| | - G A Efimov
- National Medical Research Center of Hematology, Ministry of Health of the Russian Federation, Moscow, Russia
| | - S G Ambaryan
- Sirius University of Science and Technology, Federal Territory Sirius/Sochi, Russia
| | - M S Drutskaya
- Sirius University of Science and Technology, Federal Territory Sirius/Sochi, Russia.,Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
| | - S A Nedospasov
- Sirius University of Science and Technology, Federal Territory Sirius/Sochi, Russia. .,Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
| |
Collapse
|
|
3
|
Rudenko N, Fursova K, Shepelyakovskaya A, Karatovskaya A, Brovko F. Antibodies as Biosensors' Key Components: State-of-the-Art in Russia 2020-2021. SENSORS 2021; 21:s21227614. [PMID: 34833687 PMCID: PMC8624206 DOI: 10.3390/s21227614] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 11/09/2021] [Accepted: 11/12/2021] [Indexed: 01/02/2023]
Abstract
The recognition of biomolecules is crucial in key areas such as the timely diagnosis of somatic and infectious diseases, food quality control, and environmental monitoring. This determines the need to develop highly sensitive display devices based on the achievements of modern science and technology, characterized by high selectivity, high speed, low cost, availability, and small size. Such requirements are met by biosensor systems—devices for reagent-free analysis of compounds that consist of a biologically sensitive element (receptor), a transducer, and a working solution. The diversity of biological material and methods for its immobilization on the surface or in the volume of the transducer and the use of nanotechnologies have led to the appearance of an avalanche-like number of different biosensors, which, depending on the type of biologically sensitive element, can be divided into three groups: enzyme, affinity, and cellular/tissue. Affinity biosensors are one of the rapidly developing areas in immunoassay, where the key point is to register the formation of an antigen–antibody complex. This review analyzes the latest work by Russian researchers concerning the production of molecules used in various immunoassay formats as well as new fundamental scientific data obtained as a result of their use.
Collapse
|
|
4
|
Bobik TV, Kostin NN, Skryabin GA, Tsabai PN, Simonova MA, Knorre VD, Mokrushina YA, Smirnov IV, Kosolapova JA, Vtorushina VV, Inviyaeva EV, Polushkina E, Petrova UL, Levadnaya AV, Krechetova LV, Shmakov RG, Sukhikh GT, Gabibov AG. Epitope-Specific Response of Human Milk Immunoglobulins in COVID-19 Recovered Women. Pathogens 2021; 10:705. [PMID: 34198820 PMCID: PMC8228167 DOI: 10.3390/pathogens10060705] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Revised: 05/30/2021] [Accepted: 06/03/2021] [Indexed: 12/18/2022] Open
Abstract
The breastfeeding of infants by mothers who are infected with SARS-CoV-2 has become a dramatic healthcare problem. The WHO recommends that infected women should not abandon breastfeeding; however, there is still the risk of contact transmission. Convalescent donor milk may provide a defense against the aforementioned issue and can eliminate the consequences of artificial feeding. Therefore, it is vital to characterize the epitope-specific immunological landscape of human milk from women who recovered from COVID-19. We carried out a comprehensive ELISA-based analysis of blood serum and human milk from maternity patients who had recovered from COVID-19 at different trimesters of pregnancy. It was found that patients predominantly contained SARS-CoV-2 N-protein-specific immunoglobulins and had manifested the antibodies for all the antigens tested in a protein-specific and time-dependent manner. Women who recovered from COVID-19 at trimester I-II showed a noticeable decrease in the number of milk samples with sIgA specific to the N-protein, linear NTD, and RBD-SD1 epitopes, and showed an increase in samples with RBD conformation-dependent sIgA. S-antigens were found to solely induce a sIgA1 response, whereas N-protein sIgA1 and sIgA2 subclasses were involved in 100% and 33% of cases. Overall, the antibody immunological landscape of convalescent donor milk suggests that it may be a potential defense agent against COVID-19 for infants, conferring them with a passive immunity.
Collapse
Affiliation(s)
- Tatyana V. Bobik
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| | - Nikita N. Kostin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| | - George A. Skryabin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| | - Polina N. Tsabai
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| | - Maria A. Simonova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| | - Vera D. Knorre
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| | - Yuliana A. Mokrushina
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| | - Ivan V. Smirnov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| | - Julia A. Kosolapova
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Valentina V. Vtorushina
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Evgeniya V. Inviyaeva
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Evgeniya Polushkina
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Ulyana L. Petrova
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Anna V. Levadnaya
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Lyubov V. Krechetova
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Roman G. Shmakov
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Gennadiy T. Sukhikh
- Federal State Institution “National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov”, Ministry of Health of the Russian Federation, 117997 Moscow, Russia; (J.A.K.); (V.V.V.); (E.V.I.); (E.P.); (U.L.P.); (A.V.L.); (L.V.K.); (R.G.S.); (G.T.S.)
| | - Alexander G. Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; (T.V.B.); (N.N.K.); (G.A.S.); (P.N.T.); (M.A.S.); (V.D.K.); (Y.A.M.); (I.V.S.)
| |
Collapse
|